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Introduc%on	 Methods	
	While	BRAF	is	among	the	most	well-established	oncogenes	in	
human	cancers,	more	recently	it	has	garnered	aKen%on	for	its	role	in	
suppressing	an%tumor	immunity,	especially	in	melanoma.	Because	tumor-
infiltra%ng	lymphocyte	(TIL)	density	is	strongly	prognos%c	in	colorectal	cancer	
(CRC)7,	we	decided	to	inves%gate	the	connec%on	between	TIL	density	and	the	
BRAF-ac%va%ng	V600E	muta%on	in	CRC.		
	We	downloaded	clinical	and		mRNA	expression	data	for	the	
colon	adenocarcinoma	(COAD)	cohort	of	The	Cancer	Genome	Atlas	(TCGA)	via	
the	UCSC	Cancer	Portal.	We	used	ESTIMATE	to	infer	the	presence	of	immune	
cells	in	the	TCGA	COAD	dataset	(n	=	216);	this	is	an	algorithm	that	uses	a	gene-
expression	signature	of	141	immune-related	genes	to	infer	the	presence	of	
immune	cells	in	the	tumor	infiltrate10.	Using	R,	we	ran	Wilcoxon	tests	in	
comparing	mean	ESTIMATE	scores	between	BRAF-V600E	and	BRAF-WT	
groups,	as	well	as	an	ANOVA	on	a	linear	model	for	ESTIMATE	that	included	
terms	for	microsatellite	phenotype,	BRAF	muta%on	status	and	an	interac%on	
term.		
	We	obtained	our	data	for	the	BROAD	CRC	cohort	(n=445)	
directly	from	the	authors	of	a	previous	study9,	including	immune	scores	
obtained	by	immunostaining.	We	performed	two	kinds	of	tests:	Wilcoxon	tests	
comparing	the	mean	raw	immune	scores	of	the	BRAF-V600E	and	BRAF-WT	
groups,	and	Fisher’s	tests	comparing	the	number	of	posi%ve	(score	>	0)	and	
nega%ve	(score	=	0)	binarized	immune	scores	of	each	group.		
	COAD	samples	with	the	BRAF-V600E	muta9on	have	higher	
levels	of	immune	cells	than	those	without	the	muta9on	(p	<	0.05,	Figure	1).	
The	MSI-H	subtype	of	CRC	is	characterized	by	epigene%c	silencing	of	DNA	
mismatch-repair	genes	and	higher	muta%onal	load,	neoan%gen	expression	
and	TIL	density.	Since	it	has	been	previously	established	that	BRAF	muta%on	is	
highly	correlated	with	MSI-H	phenotype3,	we	performed	an	ANOVA	to	assess	
if	BRAF	muta%on	status	predicts	ESTIMATE	score	independently	of	MSI-H	
phenotype.	While	the	BRAF	term	was	not	significant	in	this	mul%variate	linear	
model,	we	included	an	interac%on	term	that	was	significant	(p	<	0.005),	
sugges%ng	that	both	variables	contribute	to	ESTIMATE	score.		
	To	determine	the	effect	of	the	interac%on,	we	grouped	
samples	into	MSI-H	and	MSS	groups	and	compared	the	wild-type	and	BRAF	
Results	
Discussion	
	The	analysis	we	present	here	reveals	a	sta%s%cally	significant	
correla%on	between	the	BRAF-V600E	muta%on	and	increased	immune	
infiltrate	in	MSS	tumors	across	two	independent	colon	cancer	datasets.	
Because	V600E	is	an	ac%va%ng	muta%on,	this	finding	suggests	an	immunity-
s%mula%ng	role	for	BRAF	in	CRC,	in	contrast	to	BRAF’s	role	in	melanoma,	
which	appears	largely	immunosuppressive.			
V600E	subgroups	within	them.	In	the	MSS	group	only,	immune	scores	were	
higher	in	the	BRAF-V600E	subgroup	(p	=	0.05,	Figure	2).	
	Next,	we	sought	to	reproduce	our	results	in	an	independent	
cohort	of	CRC	tumor	samples	from	the	BROAD	ins%tute	that	have	been	
assigned	immune	scores	based	on	immunostaining9.	We	grouped	samples	into	
TIL-posi%ve	and	TIL-nega%ve	groups	and	compared	the	numbers	of	BRAF-
V600E	and	BRAF-WT	samples	within	each	group.	We	observed	a	significant	
correla9on	between	BRAF	muta9on	and	TIL+	immune	score	within	the	MSS	
group	(p	=	0.01352,	odds	ra9o	5.76,	Figure	3).	Notably,	the	MSS	group	is	the	
same	group	from	the	TCGA	cohort	in	which	we	observed	a	significant	
correla%on	between	BRAF	muta%on	and	ESTIMATE	score.	 		 References	
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